However, the studies conducted so far to address the multifaceted role of GSK-3β in pancreatic cancer in vivo have mostly relied on loss-of-function approaches including knockout mice or GSK-3 inhibitors (Baumgart et al., 2016; Ding et al., 2017; Ding and Billadeau, 2020). This evidence concerns the gene GSK3B and familial pancreatic carcinoma.